Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Corboy

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Neurology. Education|May 10, 2024
Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in NeuroimmunologyJohn Peters, Jeffrey A Cohen, John R Corboy, et al.
Journal of the Neurological Sciences|October 24, 2019
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-upBrandi Vollmer, Daniel Ontaneda, Haleigh Harris, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose studyFred D Lublin, James D Bowen, John Huddlestone, et al.
Multiple Sclerosis and Related Disorders|August 7, 2021
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controlsEnrique Alvarez, Kavita V Nair, Brian D Hoyt, et al.
Neurology. Clinical Practice|September 8, 2025
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill AdultsJarrett Leech, Brian M Sauer, Amiran Baduashvili, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Neurology. Clinical Practice|August 25, 2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centersBrandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, et al.
Cells|July 14, 2023
TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS InjuryBridget Shafit-Zagardo, Simone Sidoli, James E Goldman, et al.
Neurology|September 11, 2013
The American Academy of Neurology's top five Choosing Wisely recommendationsDavid H Mattson, Robert P Lisak, David E Jones, et al.
JAMA Neurology|August 28, 2020
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialBruce A C Cree, Myla D Goldman, John R Corboy, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Neurology. Education|May 10, 2024
Curriculum Innovations: Virtual Didactics as a Tool for Harmonizing Education About Rare Topics in NeuroimmunologyJohn Peters, Jeffrey A Cohen, John R Corboy, et al.
Journal of the Neurological Sciences|October 24, 2019
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-upBrandi Vollmer, Daniel Ontaneda, Haleigh Harris, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose studyFred D Lublin, James D Bowen, John Huddlestone, et al.
Multiple Sclerosis and Related Disorders|August 7, 2021
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controlsEnrique Alvarez, Kavita V Nair, Brian D Hoyt, et al.
Neurology. Clinical Practice|September 8, 2025
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill AdultsJarrett Leech, Brian M Sauer, Amiran Baduashvili, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Neurology. Clinical Practice|August 25, 2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centersBrandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, et al.
Cells|July 14, 2023
TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS InjuryBridget Shafit-Zagardo, Simone Sidoli, James E Goldman, et al.
Neurology|September 11, 2013
The American Academy of Neurology's top five Choosing Wisely recommendationsDavid H Mattson, Robert P Lisak, David E Jones, et al.
JAMA Neurology|August 28, 2020
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialBruce A C Cree, Myla D Goldman, John R Corboy, et al.
Pageof 9